国产封堵器介入治疗先天性心脏病的中长期疗效及安全性

    The long-term efficacy and safety of China-made septal occluder for transcatheter closure of congenital heart disease

    • 摘要: 目的 探讨国产封堵器介入治疗先天性心脏病的中长期疗效及安全性。方法 71例先天性心脏病患者:动脉导管未闭(PDA)27例,房间隔缺损(ASD)22例,室间隔缺损(VSD)23例,其中1例VSD并发ASD,应用国产封堵器行介入治疗。随访1~5(4.1±2.1)年,观察其中长期疗效及安全性。 结果 71例患者成功介入治疗69例,成功率97%。1例ASD和1例VSD患者介入治疗未成功。5例患者术后即刻有微-少量残余分流,1月后复查残余分流消失。1例VSD患者术后出现Ⅲ度房室传导阻滞,治疗后痊愈。随访1~5年无其他并发症出现。 结论 国产封堵器介入治疗先天性心脏病近期及中远期疗效可靠,安全性好。

       

      Abstract: AIM To evaluate the medium and long term efficacy and safety of China-made septal occluder in the transcatheter closure of congenital heart disease. METHODS Seventy-one patients with congenital heart disease, including 27 cases of PDA, 22 cases of ASD, 23 cases of VSD and 1 case of VSD combined with ASD, were treated with China-made septal occluder by transcatheter closure. All the patients were followed up for 1 to 5 years and were evaluated in terms of efficacy and safety. RESULTS Transcatheter closure was successful in 69 patients but it failed in cases, one with ASD and one with VSD. Five patients had minor to moderate residual shunt the time after the transcatheter closure but no residual shunt was observed 1 month after the operation. One patient with VSD presented III A-V block and he recovered completely after treatment. No other complications were observed in the patients during the 1-to-5-year follow up. CONCLUSION China-made septal occluder is safe and effective for transcatheter closure of congenital heart disease.

       

    /

    返回文章
    返回